Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
12.93
-0.19 (-1.45%)
Dec 5, 2025, 4:00 PM EST - Market closed
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Astria Therapeutics stock have a consensus rating of "Hold" and an average price target of $24.33, which forecasts a 88.17% increase in the stock price over the next year. The lowest target is $13 and the highest is $47.
Price Target: $24.33 (+88.17%)
Analyst Consensus: Hold
* Price targets were last updated on Oct 15, 2025.
Analyst Ratings
The average analyst rating for Astria Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Buy | 5 | 5 | 5 | 3 | 2 | 1 |
| Hold | 0 | 0 | 0 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 16, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $28 → $13 | Buy → Hold | Downgrades | $28 → $13 | +0.54% | Oct 15, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $30 → $13 | Strong Buy → Hold | Downgrades | $30 → $13 | +0.54% | Oct 14, 2025 |
Financial Forecast
Revenue This Year
8.74M
Revenue Next Year
3.57M
from 8.74M
Decreased by -59.15%
EPS This Year
-2.20
from -1.68
EPS Next Year
-2.27
from -2.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 16.8M | 8.4M | ||||
| Avg | 8.7M | 3.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -3.9% | ||||
| Avg | - | -59.2% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.94 | -1.73 | ||||
| Avg | -2.20 | -2.27 | ||||
| Low | -2.48 | -2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.